MCID: CCM001
MIFTS: 37

Cecum Adenocarcinoma malady

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Cecum Adenocarcinoma

Aliases & Descriptions for Cecum Adenocarcinoma:

Name: Cecum Adenocarcinoma 12 14
Adenocarcinoma of Cecum 12 69
Cecal Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3039
NCIt 47 C5543
SNOMED-CT 64 413446001
UMLS 69 C1332866

Summaries for Cecum Adenocarcinoma

Disease Ontology : 12 A cecum carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Cecum Adenocarcinoma, also known as adenocarcinoma of cecum, is related to clitoris cancer and extramedullary plasmacytoma, and has symptoms including abdominal pain and fever. An important gene associated with Cecum Adenocarcinoma is HMX2 (H6 Family Homeobox 2), and among its related pathways/superpathways are Pathways in cancer and Colorectal Cancer Metastasis. The drugs Fluorouracil and Levoleucovorin have been mentioned in the context of this disorder. Related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and cellular

Related Diseases for Cecum Adenocarcinoma

Diseases related to Cecum Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
id Related Disease Score Top Affiliating Genes
1 clitoris cancer 10.3 CDX2 KRT20
2 extramedullary plasmacytoma 10.3 CDX2 KRT20
3 phlebotomus fever 10.3 KRT20 SMUG1
4 cervix endometriosis 10.3 CDX2 KRT20
5 factor xiii deficiency 10.3 MSH2 PMS1
6 clear cell hidradenoma 10.3 KRT20 MSH6
7 brain stem ependymoma 10.3 CHGA SMUG1
8 spiradenoma 10.3 KRT20 MSH6
9 synovitis 10.2 CDX2 KRT7
10 radiculopathy 10.2 KRT20 KRT7
11 adult myxoid chondrosarcoma 10.2 KRT20 KRT7
12 fallopian tube mucinous tumor 10.2 KRT7 PMS1
13 diffuse idiopathic skeletal hyperostosis 10.2 KRT7 PMS1
14 granulocytopenia 10.2 CHGA KRT20
15 bronchus mucoepidermoid carcinoma 10.2 KRT20 KRT7
16 steroid-induced glaucoma - borderline 10.2 KRT20 KRT7
17 uterine ligament mucinous adenocarcinoma 10.2 CDX2 KRT7
18 oculocutaneous albinism 10.2 CHGA SMUG1
19 mesenchymoma 10.2 CDX2 CHGA KRT20
20 nonossifying fibromyxoid tumor 10.2 KRT20 KRT7
21 agenesis and aplasia of uterine body 10.2 KRT20 KRT7
22 autoimmune autonomic ganglionopathy 10.2 MSH2 MSH6
23 skin melanoma 10.2 MLH1 MSH2
24 peripheral nervous system ganglioneuroblastoma 10.2 CDX2 KRT7
25 aorta atresia 10.2 MLH1 MSH2
26 waterhouse-friderichsen syndrome 10.2 KRT20 KRT7
27 fibrolamellar carcinoma 10.2 MLH1 MSH2
28 allergic contact dermatitis 10.2 CDX2 KRT20 MLH1
29 sclerosing breast papilloma 10.1 KRT7 SMUG1
30 apocrine adenocarcinoma 10.1 CDX2 KRT20 KRT7
31 myotonia congenita 10.1 CDX2 KRT20 KRT7
32 anemia of prematurity 10.1 CDX2 KRT20 KRT7
33 papillary adenofibroma 10.1 CDX2 KRT20 KRT7
34 sagittal sinus thrombosis 10.1 CDX2 KRT20 KRT7
35 pacinian tumor 10.1 CDX2 KRT20 KRT7
36 prostate stromal sarcoma 10.1 CDX2 KRT20 KRT7
37 acute stress disorder 10.1 CDX2 KRT20 KRT7
38 ariboflavinosis 10.1 CDX2 KRT20 KRT7
39 intestinal benign neoplasm 10.1 CDX2 KRT20 KRT7
40 familial hypopituitarism 10.1 MLH1 MSH2
41 fallopian tube adenocarcinoma 10.1 CDX2 KRT20 KRT7
42 colon lymphoma 10.1 HMX2 NODAL PMS1 SMUG1
43 pituitary carcinoma 10.1 CDX2 KRT20 KRT7
44 odontotrichoungual-digital-palmar syndrome 10.1 CDX2 KRT20 KRT7
45 trophoblastic neoplasm 10.1 KRT20 KRT7
46 atopic dermatitis 10.1 CDX2 KRT20 KRT7
47 bone leiomyosarcoma 10.1 KRT7 SMUG1
48 spinal muscular atrophy with progressive myoclonic epilepsy 10.1 CDX2 KRT20 KRT7
49 gastroesophageal junction adenocarcinoma 10.1 CDX2 KRT20 KRT7
50 ideomotor apraxia 10.1 CDX2 MLH1 MSH2

Graphical network of the top 20 diseases related to Cecum Adenocarcinoma:



Diseases related to Cecum Adenocarcinoma

Symptoms & Phenotypes for Cecum Adenocarcinoma

UMLS symptoms related to Cecum Adenocarcinoma:


abdominal pain, fever

GenomeRNAi Phenotypes related to Cecum Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.02 MLH1 MSH2 MSH6 PMS1 SMUG1

MGI Mouse Phenotypes related to Cecum Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.91 MSH6 NODAL SMUG1 B2M CDX2 FGF2
2 homeostasis/metabolism MP:0005376 9.9 B2M CDX2 CHGA FGF2 HMX2 KRT7
3 mortality/aging MP:0010768 9.65 B2M CDX2 CHGA FGF2 HMX2 MLH1
4 neoplasm MP:0002006 9.23 B2M CDX2 FGF2 MLH1 MSH2 MSH6

Drugs & Therapeutics for Cecum Adenocarcinoma

Drugs for Cecum Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 2,Phase 1 51-21-8 3385
2
Levoleucovorin Approved Phase 2,Phase 1 68538-85-2
3
Palonosetron Approved, Investigational Phase 2 135729-61-2, 119904-90-4, 135729-56-5 148211
4
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 54575, 6560146 143
5 Alkylating Agents Phase 2
6 Mitomycins Phase 2
7 Nucleic Acid Synthesis Inhibitors Phase 2
8 Anti-Bacterial Agents Phase 2
9 Immunosuppressive Agents Phase 2,Phase 1
10 Protective Agents Phase 2,Phase 1
11 Antidotes Phase 2,Phase 1
12 Antimetabolites Phase 2,Phase 1
13 Antibiotics, Antitubercular Phase 2
14 Antimetabolites, Antineoplastic Phase 2,Phase 1
15 Calcium, Dietary Phase 2,Phase 1
16
Serotonin Phase 2 50-67-9 5202
17 Serotonin Agents Phase 2
18 Serotonin Antagonists Phase 2
19 Neurotransmitter Agents Phase 2
20 Liver Extracts Phase 2,Phase 1
21 Cola Nutraceutical Phase 2,Phase 1
22
Paclitaxel Approved, Vet_approved Phase 1 33069-62-4 36314
23
Irinotecan Approved, Investigational Phase 1 97682-44-5, 100286-90-6 60838
24
Carboplatin Approved Phase 1 41575-94-4 10339178 498142 38904
25
Trastuzumab Approved, Investigational Phase 1 180288-69-1 9903
26
Cetuximab Approved Phase 1 205923-56-4 56842117 2333
27
Oxaliplatin Approved, Investigational Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
28
Capecitabine Approved, Investigational Phase 1 154361-50-9 60953
29
Camptothecin Experimental Phase 1 7689-03-4
30
7-hydroxystaurosporine Experimental Phase 1 112953-11-4 72271
31 Staurosporine Experimental Phase 1 62996-74-1
32
Erlotinib Hydrochloride Phase 1 183319-69-9 176871
33 topoisomerase I inhibitors Phase 1
34 Adjuvants, Immunologic Phase 1
35 Albumin-Bound Paclitaxel Phase 1
36 Topoisomerase Inhibitors Phase 1
37 Angiogenesis Inhibitors Phase 1
38 Angiogenesis Modulating Agents Phase 1
39 Immunoglobulins Phase 1
40 Antibodies, Monoclonal Phase 1
41 Protein Kinase Inhibitors Phase 1
42 Interleukin-12 Phase 1
43 Antibodies Phase 1
44 Antimitotic Agents Phase 1
45 Antineoplastic Agents, Phytogenic Phase 1
46 Motexafin lutetium Investigational 156436-90-7
47 Dermatologic Agents
48 Photosensitizing Agents
49 Etanidazole

Interventional clinical trials:

(show all 12)
id Name Status NCT ID Phase
1 Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer Unknown status NCT00006112 Phase 2
2 Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Completed NCT00903396 Phase 2
3 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1
4 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
5 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1
6 Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1
7 Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer Completed NCT00019773 Phase 1
8 Comparison of Adenoma Detection Miss Rates at Colonoscopy Associated With Different Withdrawal Times Completed NCT01802008
9 Water-aided Colonoscopy vs Air Insufflation Colonoscopy in Colorectal Cancer Screening Completed NCT02041507
10 PillCam Colon Capsule and CT-colonography in the Evaluation of Patients With Incomplete Conventional Colonoscopy Completed NCT01525940
11 Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients Completed NCT02374411
12 EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer Terminated NCT00087191

Search NIH Clinical Center for Cecum Adenocarcinoma

Genetic Tests for Cecum Adenocarcinoma

Anatomical Context for Cecum Adenocarcinoma

Publications for Cecum Adenocarcinoma

Articles related to Cecum Adenocarcinoma:

id Title Authors Year
1
Cecum adenocarcinoma as the first manifestation of Crohn's disease in a 24-year-old woman: dilemmas in differential diagnosis and management. ( 21457632 )
2010
2
Inferior vena cava obstruction due to cecum adenocarcinoma. ( 17189847 )
2007
3
Minimal change nephrotic syndrome with cecum adenocarcinoma. ( 8861804 )
1996

Variations for Cecum Adenocarcinoma

Expression for Cecum Adenocarcinoma

Search GEO for disease gene expression data for Cecum Adenocarcinoma.

Pathways for Cecum Adenocarcinoma

GO Terms for Cecum Adenocarcinoma

Cellular components related to Cecum Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 MutLalpha complex GO:0032389 8.96 MLH1 PMS1
2 MutSalpha complex GO:0032301 8.62 MSH2 MSH6

Biological processes related to Cecum Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.88 MLH1 MSH2 MSH6 PMS1 SMUG1
2 DNA repair GO:0006281 9.77 MLH1 MSH2 MSH6 PMS1 SMUG1
3 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.58 MLH1 MSH2 MSH6
4 anterior/posterior axis specification GO:0009948 9.56 CDX2 NODAL
5 trophectodermal cell differentiation GO:0001829 9.55 CDX2 NODAL
6 determination of adult lifespan GO:0008340 9.54 MSH2 MSH6
7 positive regulation of isotype switching to IgG isotypes GO:0048304 9.52 MLH1 MSH2
8 negative regulation of DNA recombination GO:0045910 9.51 MSH2 MSH6
9 positive regulation of helicase activity GO:0051096 9.49 MSH2 MSH6
10 maintenance of DNA repeat elements GO:0043570 9.46 MSH2 MSH6
11 positive regulation of isotype switching to IgA isotypes GO:0048298 9.43 MLH1 MSH2
12 isotype switching GO:0045190 9.43 MLH1 MSH2 MSH6
13 somatic hypermutation of immunoglobulin genes GO:0016446 9.33 MLH1 MSH2 MSH6
14 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.32 MLH1 MSH2
15 mismatch repair GO:0006298 9.26 MLH1 MSH2 MSH6 PMS1
16 somatic recombination of immunoglobulin gene segments GO:0016447 8.8 MLH1 MSH2 MSH6

Molecular functions related to Cecum Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 double-stranded DNA binding GO:0003690 9.63 CDX2 MSH2 MSH6
2 ATPase activity GO:0016887 9.62 MLH1 MSH2 MSH6 PMS1
3 single-stranded DNA binding GO:0003697 9.61 MLH1 MSH2 PMS1
4 four-way junction DNA binding GO:0000400 9.48 MSH2 MSH6
5 oxidized purine DNA binding GO:0032357 9.4 MSH2 MSH6
6 MutLalpha complex binding GO:0032405 9.37 MSH2 MSH6
7 single guanine insertion binding GO:0032142 9.26 MSH2 MSH6
8 single thymine insertion binding GO:0032143 9.16 MSH2 MSH6
9 guanine/thymine mispair binding GO:0032137 9.13 MLH1 MSH2 MSH6
10 mismatched DNA binding GO:0030983 8.92 MLH1 MSH2 MSH6 PMS1

Sources for Cecum Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....